Physician profile
Charles J Monier
NPI 1043288160
$447,980.76
in general payments reported to CMS, 2019-2025
35 companies · $554 in 2025
The $554 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $522 · 2020: $645 · 2021: $706 · 2022: $679 · 2023: $828 · 2024: $444K · 2025: $554.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Acquisitions: $444K · Food and Beverage: $1,925.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Acquisitions | $443,504.20 |
| Food and Beverage | $1,924.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zimmer Biomet Holdings, INC. | $443,504.20 | 2024 | |
| Abbvie INC. | $1,084.65 | 2019-2025 | |
| Redhill Biopharma INC. | $470.47 | 2020-2024 | Talicia, Movantik, Aemcolo |
| Takeda Pharmaceuticals U.S.A., INC. | $404.49 | 2019-2025 | Entyvio |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $403.20 | 2019-2025 | Xifaxan, Trulance, Plenvu |
| Celgene Corporation | $399.08 | 2021-2024 | Zeposia |
| Janssen Biotech, INC. | $240.79 | 2019-2025 | Stelara, Tremfya |
| Pfizer INC. | $218.21 | 2019-2022 | |
| Ironwood Pharmaceuticals, INC | $190.57 | 2019-2023 | Linzess |
| Romark Laboratories, Lc | $140.89 | 2019-2020 | |
| Intercept Pharmaceuticals, INC. | $126.32 | 2019-2022 | |
| Genzyme Corporation | $118.21 | 2024-2025 | |
| Ferring Pharmaceuticals INC. | $74.49 | 2019-2023 | Rebyota |
| Qol Medical, LLC | $73.20 | 2022-2025 | Sucraid, Sucraid |
| Braintree Laboratories, INC. | $64.92 | 2020-2024 | Suflave, Sutab |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $60.02 | 2024-2025 | Voquezna |
| Madrigal Pharmaceuticals | $47.58 | 2024-2025 | Resmetirom, Rezdiffra |
| Concordia Pharmaceuticals INC. | $45.16 | 2019 | |
| Allergan, INC. | $44.72 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $42.65 | 2023 | Dificid |
| Abbott Laboratories | $28.09 | 2025 | Amplatzer Amulet |
| Boehringer Ingelheim Pharmaceuticals, INC. | $27.42 | 2023 | Cyltezo |
| Celltrion USA INC. | $25.20 | 2024 | Vegzelma |
| Axonics, INC. | $21.70 | 2023 | Axonics |
| Novo Nordisk INC | $19.09 | 2025 | Wegovy |
| Sandoz INC. | $17.87 | 2023 | Hyrimoz |
| Ardelyx, INC. | $16.86 | 2023 | Ibsrela |
| Amgen INC. | $15.63 | 2023 | Amjevita, Avsola |
| Gilead Sciences, INC. | $15.16 | 2023 | |
| Organon LLC | $15.10 | 2023 | Renflexis |
| Fresenius Kabi USA, LLC | $12.69 | 2023 | Idacio |
| Daiichi Sankyo INC. | $12.13 | 2020 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$399,721.23 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Monier listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.